Literature DB >> 33579701

Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile.

Carolina Beltrán-Pavez1,2, Sebastián Riquelme-Barrios1,2, Aarón Oyarzún-Arrau1,2, Aracelly Gaete-Argel1,2, Roxana González-Stegmaier3, Karina Cereceda-Solis3, Adam Aguirre3, Dante Travisany4,5, Ricardo Palma-Vejares4, Gonzalo P Barriga1,6, Aldo Gaggero1,7, Constanza Martínez-Valdebenito8,9, Nicole Le Corre8,9, Marcela Ferrés8,9, María Elvira Balcells10, Jorge Fernandez11, Eugenio Ramírez12, Franz Villarroel3, Fernando Valiente-Echeverría1,2, Ricardo Soto-Rifo13,2.   

Abstract

Chile has one of the worst numbers worldwide in terms of SARS-CoV-2 positive cases and COVID-19-related deaths per million inhabitants; thus, characterization of neutralizing antibody (NAb) responses in the general population is critical to understanding of immunity at the local level. Given our inability to perform massive classical neutralization assays due to the scarce availability of BSL-3 facilities in the country, we developed and fully characterized an HIV-based SARS-CoV-2 pseudotype, which was used in a 96-well plate format to investigate NAb responses in samples from individuals exposed to SARS-CoV-2 or treated with convalescent plasma. We also identified samples with decreased or enhanced neutralization activity against the D614G spike variant compared with the wild type, indicating the relevance of this variant in host immunity. The data presented here represent the first insights into NAb responses in individuals from Chile, serving as a guide for future studies in the country.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Entities:  

Year:  2021        PMID： 33579701     DOI： 10.1126/sciadv.abe6855

Source DB:  PubMed          Journal:  Sci Adv        ISSN： 2375-2548            Impact factor:   14.136


  10 in total

1.  Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile.

Authors:  Susan M Bueno; Katia Abarca; Pablo A González; Nicolás M S Gálvez; Jorge A Soto; Luisa F Duarte; Bárbara M Schultz; Gaspar A Pacheco; Liliana A González; Yaneisi Vázquez; Mariana Ríos; Felipe Melo-González; Daniela Rivera-Pérez; Carolina Iturriaga; Marcela Urzúa; Angélica Domínguez; Catalina A Andrade; Roslye V Berríos-Rojas; Gisela Canedo-Marroquín; Camila Covián; Daniela Moreno-Tapia; Farides Saavedra; Omar P Vallejos; Paulina Donato; Pilar Espinoza; Daniela Fuentes; Marcela González; Paula Guzmán; Paula Muñoz Venturelli; Carlos M Pérez; Marcela Potin; Álvaro Rojas; Rodrigo A Fasce; Jorge Fernández; Judith Mora; Eugenio Ramírez; Aracelly Gaete-Argel; Aarón Oyarzún-Arrau; Fernando Valiente-Echeverría; Ricardo Soto-Rifo; Daniela Weiskopf; Alessandro Sette; Gang Zeng; Weining Meng; José V González-Aramundiz; Alexis M Kalergis
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

2.  Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.

Authors:  Leonardo Vargas; Nicolás Valdivieso; Fabián Tempio; Valeska Simon; Daniela Sauma; Lucía Valenzuela; Caroll Beltrán; Loriana Castillo-Delgado; Ximena Contreras-Benavides; Mónica L Acevedo; Johanna Acevedo; Rafael I Gonzalez; Fernando Valiente-Echeverría; Ricardo Soto-Rifo; Mario Rosemblatt; Mercedes Lopez; Fabiola Osorio; María Rosa Bono
Journal:  BMC Med       Date:  2022-06-09       Impact factor: 11.150

3.  Development of a Rapid Fluorescent Diagnostic System for Early Detection of the Highly Pathogenic Avian Influenza H5 Clade 2.3.4.4 Viruses in Chicken Stool.

Authors:  Bao-Tuan Duong; Duc-Duong Than; Bae-Gum Ju; Thuy-Tien Thi Trinh; Chris-Ka Pun Mok; Ju-Hwan Jeong; Min-Suk Song; Yun-Hee Baek; Hyun Park; Seon-Ju Yeo
Journal:  Int J Mol Sci       Date:  2022-06-04       Impact factor: 6.208

4.  Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach.

Authors:  Alexander Kwarteng; Ebenezer Asiedu; Augustina Angelina Sylverken; Amma Larbi; Samuel Asamoah Sakyi; Samuel Opoku Asiedu
Journal:  Infect Genet Evol       Date:  2021-03-24       Impact factor: 3.342

5.  Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group.

Authors:  Alejandro Escobar; Felipe E Reyes-López; Mónica L Acevedo; Luis Alonso-Palomares; Fernando Valiente-Echeverría; Ricardo Soto-Rifo; Hugo Portillo; Jimena Gatica; Ivan Flores; Estefanía Nova-Lamperti; Carlos Barrera-Avalos; María Rosa Bono; Leonardo Vargas; Valeska Simon; Elias Leiva-Salcedo; Cecilia Vial; Juan Hormazabal; Lina Jimena Cortes; Daniel Valdés; Ana M Sandino; Mónica Imarai; Claudio Acuña-Castillo
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

6.  Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence.

Authors:  Francisco Fuentes-Villalobos; Jose L Garrido; Matías A Medina; Nicole Zambrano; Natalia Ross; Felipe Bravo; Aracelly Gaete-Argel; Aarón Oyarzún-Arrau; Fatima Amanat; Ricardo Soto-Rifo; Fernando Valiente-Echeverría; Renato Ocampo; Christian Esveile; Leonila Ferreira; Johanna Cabrera; Vivianne Torres; Maria L Rioseco; Raúl Riquelme; Sebastián Barría; Raymond Alvarez; Yazmín Pinos; Florian Krammer; Mario Calvo; Maria I Barria
Journal:  Front Immunol       Date:  2022-02-07       Impact factor: 7.561

7.  Screening of Natural Products Inhibitors of SARS-CoV-2 Entry.

Authors:  Pamela González-Maldonado; Nelson Alvarenga; Alberto Burgos-Edwards; Ma Eugenia Flores-Giubi; Javier E Barúa; Ma Cristina Romero-Rodríguez; Ricardo Soto-Rifo; Fernando Valiente-Echeverría; Patricia Langjahr; Guadalupe Cantero-González; Pablo H Sotelo
Journal:  Molecules       Date:  2022-03-07       Impact factor: 4.411

8.  Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection.

Authors:  Marcelo J Wolff; Mónica L Acevedo; María Antonieta Núñez; Mónica Lafourcade; Aracelly Gaete-Argel; Ricardo Soto-Rifo; Fernando Valiente-Echeverría
Journal:  J Travel Med       Date:  2022-05-31       Impact factor: 39.194

9.  Phytochemical Discrimination, Biological Activity and Molecular Docking of Water-Soluble Inhibitors from Saussurea costus Herb against Main Protease of SARS-CoV-2.

Authors:  Hajo Idriss; Babeker Siddig; Pamela González Maldonado; H M Elkhair; A I Alakhras; Emad M Abdallah; Pablo Hernán Sotelo Torres; Amin O Elzupir
Journal:  Molecules       Date:  2022-08-01       Impact factor: 4.927

Review 10.  COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes.

Authors:  Daniele Focosi; Massimo Franchini; Liise-Anne Pirofski; Thierry Burnouf; Nigel Paneth; Michael J Joyner; Arturo Casadevall
Journal:  Clin Microbiol Rev       Date:  2022-03-09       Impact factor: 50.129
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.